J. E. Garber

1.2k total citations
26 papers, 783 citations indexed

About

J. E. Garber is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, J. E. Garber has authored 26 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 8 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in J. E. Garber's work include BRCA gene mutations in cancer (8 papers), Advanced Breast Cancer Therapies (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). J. E. Garber is often cited by papers focused on BRCA gene mutations in cancer (8 papers), Advanced Breast Cancer Therapies (4 papers) and Ovarian cancer diagnosis and treatment (3 papers). J. E. Garber collaborates with scholars based in United States, Canada and Spain. J. E. Garber's co-authors include Claudine Isaacs, Susan L. Neuhausen, Albert M. Levin, O. Olopade, Lisa Cannon‐Albright, Steven A. Narod, BL Weber, M. Daly, Timothy R. Rebbeck and C. Snyder and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

J. E. Garber

23 papers receiving 755 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. E. Garber United States 9 549 268 250 151 145 26 783
Bert van Geel Netherlands 7 756 1.4× 254 0.9× 358 1.4× 199 1.3× 110 0.8× 7 896
O. Olopade United States 3 453 0.8× 179 0.7× 315 1.3× 127 0.8× 129 0.9× 4 693
Leon C. Verhoog Netherlands 8 860 1.6× 337 1.3× 411 1.6× 251 1.7× 118 0.8× 9 1.1k
Kerstin Rhiem Germany 15 572 1.0× 184 0.7× 312 1.2× 175 1.2× 109 0.8× 28 786
DF Easton United Kingdom 7 724 1.3× 238 0.9× 291 1.2× 283 1.9× 127 0.9× 16 940
D. G. Crüger Denmark 12 339 0.6× 137 0.5× 100 0.4× 97 0.6× 141 1.0× 17 563
Susan Peock United Kingdom 8 344 0.6× 262 1.0× 142 0.6× 71 0.5× 101 0.7× 12 645
Pascaline Berthet France 15 513 0.9× 425 1.6× 196 0.8× 210 1.4× 112 0.8× 34 1.2k
Valérie Bonadona France 6 322 0.6× 414 1.5× 292 1.2× 592 3.9× 146 1.0× 11 947
Patrice Watson United States 8 365 0.7× 398 1.5× 241 1.0× 549 3.6× 65 0.4× 8 800

Countries citing papers authored by J. E. Garber

Since Specialization
Citations

This map shows the geographic impact of J. E. Garber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. E. Garber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. E. Garber more than expected).

Fields of papers citing papers by J. E. Garber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. E. Garber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. E. Garber. The network helps show where J. E. Garber may publish in the future.

Co-authorship network of co-authors of J. E. Garber

This figure shows the co-authorship network connecting the top 25 collaborators of J. E. Garber. A scholar is included among the top collaborators of J. E. Garber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. E. Garber. J. E. Garber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Isakoff, SJ, Cristina Cruz, J. E. Garber, et al.. (2013). Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC). Cancer Research. 73(24_Supplement). OT1–4. 1 indexed citations
3.
Isakoff, SJ, Tiffany A. Traina, LA Carey, et al.. (2012). Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.. Cancer Research. 72(24_Supplement). PD09–3. 5 indexed citations
4.
Isakoff, SJ, Paul E. Goss, Erica L. Mayer, et al.. (2011). TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.. Journal of Clinical Oncology. 29(15_suppl). 1025–1025. 30 indexed citations
5.
Domchek, S. M., Tara M. Friebel, Susan L. Neuhausen, et al.. (2011). Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?. Journal of Clinical Oncology. 29(15_suppl). 1501–1501. 16 indexed citations
6.
Masciari, Serena, Drupadi Dillon, Mark E. Robson, et al.. (2011). Breast cancer phenotype in women with TP53 germ-line mutations: An LFS consortium effort.. Journal of Clinical Oncology. 29(15_suppl). 1519–1519. 2 indexed citations
7.
8.
Goss, Paul E., J. N. Ingle, Anthony Cheung, et al.. (2011). Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.. Journal of Clinical Oncology. 29(18_suppl). LBA504–LBA504. 7 indexed citations
9.
Garber, J. E., Susan Halabi, Sara M. Tolaney, et al.. (2010). Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. JNCI Journal of the National Cancer Institute. 102(13). 942–949. 40 indexed citations
10.
Pierce, L.J., Kelly‐Anne Phillips, Saundra S. Buys, et al.. (2010). 7N Local therapy options in BRCA1/2 carriers with operable breast cancer: the importance of adjuvant chemotherapy. European Journal of Cancer Supplements. 8(3). 55–55.
11.
Sprott, Kam, et al.. (2009). DNA repair protein biomarkers in triple negative breast cancer.. Cancer Research. 69(2_Supplement). 1064–1064. 2 indexed citations
12.
Peshkin, Beth N., Tiffani A. DeMarco, J. E. Garber, et al.. (2008). Brief Assessment of Parents' Attitudes Toward Testing Minor Children for Hereditary Breast/Ovarian Cancer Genes: Development and Validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). Journal of Pediatric Psychology. 34(6). 627–638. 28 indexed citations
13.
Pierce, L.J., Kathleen A. Griffith, Saundra Buys, et al.. (2008). Outcomes following breast conservation versus mastectomy in BRCA1/2 carriers with early-stage breast cancer. Journal of Clinical Oncology. 26(15_suppl). 536–536. 2 indexed citations
14.
Blackwood‐Chirchir, Anne, Maria Tretiakova, Weihong Yuan, et al.. (2004). P27 and pAKT Expression in BRCA1-associated and sporadic breast tumors. Journal of Clinical Oncology. 22(14_suppl). 9609–9609. 2 indexed citations
15.
Digianni, L. & J. E. Garber. (2002). COMPELEMENTARY AND ALTERNATIVE MEDICINE USE AMANG WOMEN WITH BREAST CANCER. 20(18). 34–38. 1 indexed citations
16.
Lu, K. H., J. E. Garber, D. W. Cramer, et al.. (1999). Prophylactic oophorectomies in women at high risk for ovarian cancer. Gynecologic Oncology. 72(3). 450–451. 2 indexed citations
17.
Rebbeck, Timothy R., Albert M. Levin, Andrea Eisen, et al.. (1999). Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers. JNCI Journal of the National Cancer Institute. 91(17). 1475–1479. 464 indexed citations
18.
Audrain, Janet, Barbara K. Rimer, David Cella, et al.. (1998). Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want?. Journal of Clinical Oncology. 16(1). 133–138. 59 indexed citations
19.
Foretová, Lenka, J. E. Garber, Norman L. Sadowsky, et al.. (1998). Carcinoembryonic antigen in breast nipple aspirate fluid.. PubMed. 7(3). 195–8. 23 indexed citations
20.
Hahn, William C., et al.. (1997). Diagnosis in Oncology. Leukemia cutis.. Journal of Clinical Oncology. 15(5). 2170–2171. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bert van Geel Breakdown of academic impact, for papers by O. Olopade Breakdown of academic impact, for papers by Leon C. Verhoog Breakdown of academic impact, for papers by Kerstin Rhiem Breakdown of academic impact, for papers by DF Easton Breakdown of academic impact, for papers by D. G. Crüger Breakdown of academic impact, for papers by Susan Peock Breakdown of academic impact, for papers by Pascaline Berthet Breakdown of academic impact, for papers by Valérie Bonadona Breakdown of academic impact, for papers by Patrice Watson
Rankless by CCL
2026